Author ' s response to reviews Title : Chemotherapy for advanced pancreatic cancer : A systematic review and network meta-analysis

[1]  M. Metcalfe,et al.  Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer , 2013, American journal of clinical oncology.

[2]  A. Nagrial,et al.  Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer , 2013, Cochrane Database of Systematic Reviews.

[3]  M. Hidalgo,et al.  Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). , 2013 .

[4]  Y. Ko,et al.  Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) , 2012, Gut.

[5]  Tianjing Li,et al.  Network meta-analysis-highly attractive but more methodological research is needed , 2011, BMC medicine.

[6]  Joseph C Cappelleri,et al.  Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[8]  Hong-Xia Wang,et al.  A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma , 2011, Journal of hematology & oncology.

[9]  E. Van Cutsem,et al.  Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.

[10]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Deborah M Caldwell,et al.  Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. , 2010, Journal of clinical epidemiology.

[12]  R. Labianca,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Ueno,et al.  A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer , 2009, British Journal of Cancer.

[15]  W. Scheithauer,et al.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jeroen P Jansen,et al.  Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  Catrin Tudur Smith,et al.  Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison , 2008, BMC Cancer.

[18]  J. Neoptolemos,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses , 2008, British Journal of Cancer.

[19]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[20]  R. Labianca,et al.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.

[21]  H. Kocher,et al.  Analysis of mortality rates for pancreatic cancer across the world. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[22]  G. Chatellier,et al.  Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer , 2007, Drugs & aging.

[23]  M. Pino,et al.  Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress? , 2007, Cancer.

[24]  M. Reni,et al.  A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma , 2007 .

[25]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Joseph Beyene,et al.  Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data , 2007, BMC medical research methodology.

[28]  Eileen M O'Reilly,et al.  Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Syrigos,et al.  A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer , 2006, British Journal of Cancer.

[31]  G. Lu,et al.  Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .

[32]  D. V. Von Hoff,et al.  A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  D G Altman,et al.  Indirect comparisons of competing interventions. , 2005, Health technology assessment.

[34]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[35]  M. Stauch,et al.  A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer , 2005 .

[36]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Ychou,et al.  Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Van Cutsem,et al.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[42]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[43]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[45]  D. Xie,et al.  Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. , 2006, Chinese journal of digestive diseases.

[46]  W. Scheithauer,et al.  Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.